Shares of Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $3.65, but opened at $3.9370. Raia Drogasil shares last traded at $3.9370, with a volume of 6,309 shares changing hands.
Analyst Ratings Changes
Separately, Zacks Research upgraded Raia Drogasil to a “hold” rating in a research note on Thursday, April 9th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.
Read Our Latest Research Report on RADLY
Raia Drogasil Stock Up 7.6%
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. The firm had revenue of $2.17 billion during the quarter, compared to the consensus estimate of $2.32 billion.
About Raia Drogasil
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
Read More
- Five stocks we like better than Raia Drogasil
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
- AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
- 3 Stocks That Prove the AI Trade Isn’t Over, It Moved
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
